Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies

The Lancet. Respiratory Medicine
Alimuddin ZumlaGiovanni Battista Migliori

Abstract

WHO estimates that 9 million people developed active tuberculosis in 2013 and 1·5 million people died from it. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis continue to spread worldwide with an estimated 480,000 new cases in 2013. Treatment success rates of MDR and XDR tuberculosis are still low and development of new, more effective tuberculosis drugs and adjunct therapies to improve treatment outcomes are urgently needed. Although standard therapy for drug-sensitive tuberculosis is highly effective, shorter, more effective treatment regimens are needed to reduce the burden of infectious cases. We review the latest WHO guidelines and global recommendations for treatment and management of drug-sensitive and drug-resistant tuberculosis, and provide an update on new drug development, results of several phase 2 and phase 3 tuberculosis treatment trials, and other emerging adjunct therapeutic options for MDR and XDR tuberculosis. The use of fluoroquinolone-containing (moxifloxacin and gatifloxacin) regimens have failed to shorten duration of therapy, and the new tuberculosis drug pipeline is sparse. Scale-up of existing interventions with increased investments into tuberculosis health services, develop...Continue Reading

Associated Clinical Trials

References

Jan 1, 1993·Sozial- Und Präventivmedizin
Aug 5, 2003·QJM : Monthly Journal of the Association of Physicians·M NtsekheB M Mayosi
Mar 24, 2007·Life Sciences·Muhammad Sohail SajidMuhammad Umair Iqbal
Aug 5, 2008·JAMA : the Journal of the American Medical Association·Andrew BoulleGary Maartens
May 13, 2009·Antimicrobial Agents and Chemotherapy·Larissa A WenningMarian Iwamoto
Jun 6, 2009·The New England Journal of Medicine·Andreas H DiaconDavid F Mc Neeley
Oct 27, 2009·Nature Reviews. Microbiology·Clifton E BarryDouglas Young
Feb 26, 2010·The New England Journal of Medicine·Salim S Abdool KarimQuarraisha Abdool Karim
Jan 6, 2011·Expert Opinion on Drug Safety·Tanuja N GengiahQuarraisha Abdool Karim
Jun 7, 2011·The Journal of Antimicrobial Chemotherapy·Hong-Bin XuLing Li
Aug 11, 2011·The European Respiratory Journal·D FalzonM Zignol
Oct 21, 2011·The New England Journal of Medicine·François-Xavier BlancUNKNOWN CAMELIA (ANRS 1295–CIPRA KH001) Study Team
Oct 21, 2011·The New England Journal of Medicine·Diane V HavlirUNKNOWN AIDS Clinical Trials Group Study A5221
Oct 21, 2011·The New England Journal of Medicine·Salim S Abdool KarimQuarraisha Abdool Karim
Jan 28, 2012·The Lancet Infectious Diseases·Russell R KempkerHenry M Blumberg
Mar 30, 2012·The Journal of Infectious Diseases·Michael UhlinMarkus Maeurer
Apr 6, 2012·The Journal of Infectious Diseases·Alimuddin ZumlaRifat Atun
Apr 13, 2012·The European Respiratory Journal·Giovanni SotgiuGiovanni Battista Migliori
Jun 8, 2012·The New England Journal of Medicine·Maria Tarcela GlerCharles D Wells
Sep 22, 2012·The European Respiratory Journal·Saverio De LorenzoGiovanni Battista Migliori
Sep 29, 2012·The European Respiratory Journal·Vija SkripconokaCharles D Wells
Oct 19, 2012·The New England Journal of Medicine·Myungsun LeeClifton E Barry
Dec 4, 2012·Expert Review of Anti-infective Therapy·Emanuele PontaliGiovanni Battista Migliori
Jan 15, 2013·The European Respiratory Journal·Amr S AlbannaDick Menzies
Mar 28, 2013·The Lancet Infectious Diseases·Ibrahim AbubakarAlimuddin Zumla
Apr 9, 2013·The Journal of Infectious Diseases·Juraj Ivanyi, Alimuddin Zumla
May 1, 2013·Nature Reviews. Drug Discovery·Alimuddin ZumlaStewart T Cole
Jun 29, 2013·American Journal of Respiratory and Critical Care Medicine·Shashank GuptaWilliam R Bishai
Sep 24, 2013·Therapeutic Advances in Respiratory Disease·Madhavi J Parekh, Neil W Schluger
Jan 17, 2014·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·N PadayatchiG Friedland
Apr 11, 2014·The Lancet. Respiratory Medicine·Stefan H E KaufmannMarkus Maeurer
Jun 19, 2014·American Journal of Respiratory and Critical Care Medicine·Jan HeyckendorfChristoph Lange

❮ Previous
Next ❯

Citations

Oct 31, 2015·Expert Review of Vaccines·Françoise Mascart, Camille Locht
Feb 10, 2016·Antimicrobial Resistance and Infection Control·Noriko ShinodaMineo Watanabe
Jan 23, 2016·Der Internist·M P GrobuschS Bélard
Jul 30, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alimuddin ZumlaUNKNOWN Host-Directed Therapies Network (HDT-NET) Consortium
Apr 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·Aleidy SilvaMarcus A Horwitz
Sep 22, 2015·International Journal of Pediatric Otorhinolaryngology·Peter S HanJared C Inman
Mar 28, 2016·The Lancet. Respiratory Medicine·Alimuddin ZumlaRobert S Wallis
Sep 27, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shreemanta K ParidaMarkus Maeurer
Jul 18, 2015·Nature Reviews. Drug Discovery·Alimuddin ZumlaRobert S Wallis
Jun 13, 2015·The Lancet. Respiratory Medicine·Robert S Wallis
Apr 28, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Arne von DelftAlimuddin Zumla
Jun 19, 2016·Bioorganic & Medicinal Chemistry Letters·Goverdhan SurineniSrinivas Kantevari
May 31, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ana D AlvesAna Grenha
Aug 19, 2016·BMC Infectious Diseases·Evangelina Inácio NambureteValdes Roberto Bollela
Oct 19, 2016·Biomaterials Science·Arti VashistMadhavan Nair
Jan 13, 2017·Critical Reviews in Analytical Chemistry·Guilherme Felipe Dos Santos FernandesJean Leandro Dos Santos
Feb 15, 2017·British Journal of Pharmacology·Collette S GuyElizabeth Fullam
Jan 21, 2016·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Marcos Abdo ArbexGiovanni Battista Migliori
Oct 16, 2015·Einstein·Jacyr Pasternak
Sep 2, 2016·The Cochrane Database of Systematic Reviews·Sophie JullienRohit Bhatia
Aug 5, 2017·International Journal of Mycobacteriology·Angelo IacobinoLanfranco Fattorini
Jun 27, 2018·Respirology : Official Journal of the Asian Pacific Society of Respirology·Shang-Yi LinYen-Hsu Chen
Mar 16, 2016·Antimicrobial Agents and Chemotherapy·Estefanía UrdánizMariana Piuri
Jan 27, 2017·The European Respiratory Journal·Christian LienhardtMario Raviglione
Oct 28, 2016·Nature Reviews. Disease Primers·Madhukar PaiMario Raviglione
May 18, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Xuemei YangGuoqiang Cao
Feb 13, 2018·Artificial Cells, Nanomedicine, and Biotechnology·Alexandre C C VieiraSalette Reis
Jan 25, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Cátia TeixeiraFilomena Martins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

© 2021 Meta ULC. All rights reserved